TG Therapeutics Conference Call TG Therapeutics (TGTX) announced that, tomorrow, Tuesday, August 1, 2023, a conference call will be held at 8.30 AM ET, to discuss the results of the second quarter 2023 and provide a business outlook for the remainder of the year.    Michael S. Weiss, Chairman and Chief Executive Officer will host the call. To participate in this conference please . . …

ImmunoGen in the News WALTHAM, Mass.--(BUSINESS WIRE) --Jul. 31, 2023-- ImmunoGen (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023. From ImmunoGen Mark Enyedy, ImmunoGen’s President and Chief Executive Officer said, “This quarter we achieved a . . . This content …

Merck and Moderna Inc Announcement Merck (MRK) and Moderna Inc (MRNA . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Syndax Pharmaceuticals and Incyte Syndax Pharmaceuticals (SNDX) and Incyte (INCY) announced positive data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

The way drugs are being delivered into patients’ bodies have become more than ever considered important with regard to the safety and efficacy of the treatments. We consider Halozyme Biopharmaceutical is a leader in bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used …

Merck and Kintara in the NEWS Treating cancers that have no treatments should be a priority for researchers to create a treatment for them.  Patients who are afflicted with untreatable deadly diseases might not have a single drop of hope in survival  from these untreatable cancers. In yesterday's news, we fell on a treatment by Merck that demonstrated statistically significant and clinically meaningful improvement in …

Prohost Letter #456 Treatments for Untreatable Diseases The revolution in biotechnology is not meant to offer just improvements on approved and marketed drugs. We are witnessing novel investigational products demonstrating safety, efficacy, statistically significant and clinically meaningful results in treating diseases that used to be considered untreatable. They include life-threatening, devastating and fast killers’ diseases. Important To Know   Biotech firms with solid fundamentals are …

BioMarin Pharmaceutical US FDA Approval for ROCTAVIAN On June 30, 2023, BioMarin Pharmaceutical (BMRN) announced that the U.S. FDA has approved ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by . . . This content is for paid subscribers. Please click here to …